Taysha Gene Therapies grants new hires 384,000 RSUs, options for 92,400 shares under inducement plan
Bitget2026/10/02 12:00- Taysha Gene Therapies granted four new employees 384,000 restricted stock units under its 2023 Inducement Plan.
- Each RSU award vests in four equal annual installments starting on the first anniversary of the vesting commencement date.
- The company also issued options covering 92,400 shares with an exercise price of $4.74.
- Options run for 10 years. Vesting spans four years, with 25% after one year, then monthly over 36 months.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Even with Eli Lilly's endorsement, TRex Bio (TRXB.US) struggles to enjoy a premium, as the issue price drops to the lower limit of $14.
Early-stage biotechnology company TRex Bio has priced its IPO at the lower end of the range at $14 per share, raising $116.7 million and achieving a market capitalization of $384 million. The company will be listed on Nasdaq on Friday, with Eli Lilly expressing interest in increasing its stake.
Small molecule biotechnology company Iambic Therapeutics (IAM.US) IPO priced at $15-17 per share, aiming to raise $150 millions.
Iambic Therapeutics plans to raise $150 millions by issuing 9.4 million shares, with an offering price range of $15 to $17 per share.
Pimco warns: 10-year US Treasury yield may hit 6%, for the first time since 2000
PIMCO's Chief Investment Officer stated that due to high oil prices intensifying inflation concerns and market unease over the growing U.S. public debt, the benchmark 10-year U.S. Treasury yield could rise to 6% for the first time since 2000.
Crypto prices
More
